WHO releases first guideline on the use of GLP-1 therapies for treating obesity
To address the growing global health challenge of obesity, which affects more than 1 billion people, the World Health…
Stopping GLP-1 drugs before pregnancy leads to more weight gain
New research shows that women who halt GLP-1 medications near conception face greater gestational weight gain and elevated…
Searches for “Ozempic face” surge as people look for filler-based solutions
New search data reveal that as interest in “Ozempic face” surges, people increasingly turn to nonsurgical fillers rather…
Tirzepatide may only temporarily suppress brain activity involved in “food noise”
A rare glimpse into the brain activity of a patient with obesity and loss of control eating on…
GLP-1 drugs linked to improved survival in colon cancer patients
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists –…
Diabetes remission possible with GLP-1 drugs, Italian study confirms
Real-world data from over 14,000 Italian adults reveal that GLP-1 receptor agonists can induce remission in type 2…
Study:Half of adults without diabetes taking weight-loss drug discontinue treatment within a year
The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals…